long intergenic non-protein coding RNA 2575Genealiases: []
Q-omics provides the consensus-scored LINC02575 profile across patient tissues and cancer cell-line models. LINC02575 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC02575 is differentially expressed in 13, with the highest sampling consensus in STAD. Additionally, LINC02575 RNA expression shows 12,696 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, STAD, and THYM as cancer lineages where LINC02575 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02575 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02575 survival associations across molecular data types. LINC02575 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02575 RNA expression–survival associations across cancer types. High LINC02575 expression shows unfavorable associations in HNSC, ACC, UCEC, OV and CHOL, but favorable associations in BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC02575 RNA expression.
This table summarizes LINC02575 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02575. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02575 shows lower tumor expression in LUAD, BRCA and KICH and higher tumor expression in STAD, HNSC and BLCA. The STAD box plot shows higher LINC02575 RNA expression in tumor versus normal tissue (log2 FC = +2.263, t-test p < 0.001).
This table shows molecular features associated with LINC02575 in patient tissues and cancer cell lines. In patient samples, LINC02575 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
